CA2385907A1 - Methods to identify compounds that modulate neuronal activity - Google Patents
Methods to identify compounds that modulate neuronal activity Download PDFInfo
- Publication number
- CA2385907A1 CA2385907A1 CA002385907A CA2385907A CA2385907A1 CA 2385907 A1 CA2385907 A1 CA 2385907A1 CA 002385907 A CA002385907 A CA 002385907A CA 2385907 A CA2385907 A CA 2385907A CA 2385907 A1 CA2385907 A1 CA 2385907A1
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- sequence
- plmf
- carboxy terminus
- ion channel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims description 23
- 230000001537 neural effect Effects 0.000 title description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 46
- 230000014509 gene expression Effects 0.000 claims abstract description 21
- 108090000312 Calcium Channels Proteins 0.000 claims abstract description 17
- 102000003922 Calcium Channels Human genes 0.000 claims abstract description 17
- 102000010029 Homer Scaffolding Proteins Human genes 0.000 claims abstract description 12
- 108010077223 Homer Scaffolding Proteins Proteins 0.000 claims abstract description 12
- 102000004310 Ion Channels Human genes 0.000 claims abstract description 8
- 108090000862 Ion Channels Proteins 0.000 claims abstract description 8
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 9
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 3
- 230000028252 learning or memory Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 abstract description 13
- 108090000623 proteins and genes Proteins 0.000 abstract description 12
- 238000007423 screening assay Methods 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 4
- 102000013265 Syntaxin 1 Human genes 0.000 abstract description 3
- 108010090618 Syntaxin 1 Proteins 0.000 abstract description 3
- 239000011575 calcium Substances 0.000 description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
- 229910052791 calcium Inorganic materials 0.000 description 11
- 230000003834 intracellular effect Effects 0.000 description 10
- 108091006146 Channels Proteins 0.000 description 9
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 8
- 229910001424 calcium ion Inorganic materials 0.000 description 8
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 7
- 102000015799 Qa-SNARE Proteins Human genes 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108700012358 P/Q-type calcium channel Proteins 0.000 description 5
- 102000050761 P/Q-type calcium channel Human genes 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000003518 presynaptic effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 4
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 108090000699 N-Type Calcium Channels Proteins 0.000 description 3
- 102000004129 N-Type Calcium Channels Human genes 0.000 description 3
- 108010027023 Q-Type Calcium Channels Proteins 0.000 description 3
- 230000009460 calcium influx Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
- 101000944251 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) Calcium/calmodulin-dependent protein kinase cmkA Proteins 0.000 description 2
- 229930001406 Ryanodine Natural products 0.000 description 2
- 102000000583 SNARE Proteins Human genes 0.000 description 2
- 108010041948 SNARE Proteins Proteins 0.000 description 2
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 210000000782 cerebellar granule cell Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010004 neural pathway Effects 0.000 description 2
- 230000003957 neurotransmitter release Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- JJSYXNQGLHBRRK-SFEDZAPPSA-N ryanodine Chemical compound O([C@@H]1[C@]([C@@]2([C@]3(O)[C@]45O[C@@]2(O)C[C@]([C@]4(CC[C@H](C)[C@H]5O)O)(C)[C@@]31O)C)(O)C(C)C)C(=O)C1=CC=CN1 JJSYXNQGLHBRRK-SFEDZAPPSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 2
- YJIYWYAMZFVECX-UHFFFAOYSA-N 2-[N-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetic acid acetyloxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O YJIYWYAMZFVECX-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101000879393 Aplysia californica Synaptobrevin Proteins 0.000 description 1
- XFTWUNOVBCHBJR-UHFFFAOYSA-N Aspergillomarasmine A Chemical compound OC(=O)C(N)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O XFTWUNOVBCHBJR-UHFFFAOYSA-N 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001131829 Homo sapiens P protein Proteins 0.000 description 1
- 101000963974 Hydrophis stokesii Alpha-elapitoxin-Ast2b Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101000964025 Naja naja Long neurotoxin 3 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000004874 Synaptophysin Human genes 0.000 description 1
- 108090001076 Synaptophysin Proteins 0.000 description 1
- 102000003691 T-Type Calcium Channels Human genes 0.000 description 1
- 108090000030 T-Type Calcium Channels Proteins 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- -1 carbachol activated calcium Chemical class 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000047119 human OCA2 Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- HTYIXCKSEQQCJO-UHFFFAOYSA-N phenaglycodol Chemical compound CC(C)(O)C(C)(O)C1=CC=C(Cl)C=C1 HTYIXCKSEQQCJO-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 102000003137 synaptotagmin Human genes 0.000 description 1
- 108060008004 synaptotagmin Proteins 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 1
- 230000011215 vesicle docking Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15909599P | 1999-10-13 | 1999-10-13 | |
| US60/159,095 | 1999-10-13 | ||
| PCT/CA2000/001233 WO2001027630A2 (en) | 1999-10-13 | 2000-10-13 | Methods to identify compounds that modulate neuronal activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2385907A1 true CA2385907A1 (en) | 2001-04-19 |
Family
ID=22571069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002385907A Abandoned CA2385907A1 (en) | 1999-10-13 | 2000-10-13 | Methods to identify compounds that modulate neuronal activity |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6531288B1 (enExample) |
| EP (1) | EP1230551B1 (enExample) |
| JP (1) | JP2003511087A (enExample) |
| AT (1) | ATE312350T1 (enExample) |
| AU (1) | AU7896700A (enExample) |
| CA (1) | CA2385907A1 (enExample) |
| DE (1) | DE60024664T2 (enExample) |
| ES (1) | ES2253263T3 (enExample) |
| WO (1) | WO2001027630A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2424269T3 (es) * | 2002-11-01 | 2013-09-30 | Iris International, Inc. | Inmuno-PCR sándwich por desplazamiento |
| US20050266524A1 (en) * | 2003-12-03 | 2005-12-01 | Bulla Lee A | Beta integrin gene and protein |
| JP5188808B2 (ja) * | 2004-11-03 | 2013-04-24 | アイリス モレキュラー ダイアグノスティクス， インコーポレイテッド | 同種の分析物検出 |
| PT1815028E (pt) * | 2004-11-03 | 2012-01-24 | Iris Molecular Diagnostics Inc | Microbolhas para separação por afinidade |
| US20090246781A1 (en) * | 2008-02-21 | 2009-10-01 | Robert Klem | Method for early determination of recurrence after therapy for prostate cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874236A (en) | 1988-04-04 | 1999-02-23 | Sibia Neurosciences. Inc. | DNA encoding human calcium channel α-1A, β1, β-2, and β-4 subunits, and assays using cells that express the subunits |
| US5623051A (en) * | 1994-11-10 | 1997-04-22 | University Of Washington | Methods and compositions for screening for presynaptic calcium channel blockers |
| JPH09299092A (ja) * | 1996-03-12 | 1997-11-25 | Takeda Chem Ind Ltd | 新規タンパク質およびそのｄｎａ |
-
2000
- 2000-10-13 CA CA002385907A patent/CA2385907A1/en not_active Abandoned
- 2000-10-13 ES ES00969145T patent/ES2253263T3/es not_active Expired - Lifetime
- 2000-10-13 AU AU78967/00A patent/AU7896700A/en not_active Abandoned
- 2000-10-13 JP JP2001530589A patent/JP2003511087A/ja active Pending
- 2000-10-13 WO PCT/CA2000/001233 patent/WO2001027630A2/en not_active Ceased
- 2000-10-13 US US09/688,295 patent/US6531288B1/en not_active Expired - Fee Related
- 2000-10-13 EP EP00969145A patent/EP1230551B1/en not_active Expired - Lifetime
- 2000-10-13 AT AT00969145T patent/ATE312350T1/de not_active IP Right Cessation
- 2000-10-13 DE DE60024664T patent/DE60024664T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003511087A (ja) | 2003-03-25 |
| WO2001027630A3 (en) | 2001-12-06 |
| ES2253263T3 (es) | 2006-06-01 |
| ATE312350T1 (de) | 2005-12-15 |
| AU7896700A (en) | 2001-04-23 |
| US6531288B1 (en) | 2003-03-11 |
| WO2001027630A2 (en) | 2001-04-19 |
| DE60024664T2 (de) | 2006-07-06 |
| EP1230551A2 (en) | 2002-08-14 |
| EP1230551B1 (en) | 2005-12-07 |
| DE60024664D1 (de) | 2006-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matsuda et al. | Phosphorylation of serine‐880 in GluR2 by protein kinase C prevents its C terminus from binding with glutamate receptor‐interacting protein | |
| Mochida et al. | Inhibition of neurotransmission by peptides containing the synaptic protein interaction site of N-type Ca2+ channels | |
| Feng et al. | Homer regulates gain of ryanodine receptor type 1 channel complex | |
| Prather et al. | Ability of delta-opioid receptors to interact with multiple G-proteins is independent of receptor density. | |
| Ferrandi et al. | Evidence for an interaction between adducin and Na+-K+-ATPase: relation to genetic hypertension | |
| Garcia et al. | SAP90 binds and clusters kainate receptors causing incomplete desensitization | |
| Nykjaer et al. | Sortilin is essential for proNGF-induced neuronal cell death | |
| Gao et al. | cAMP-dependent regulation of cardiac L-type Ca2+ channels requires membrane targeting of PKA and phosphorylation of channel subunits | |
| Carroll et al. | Role of AMPA receptor endocytosis in synaptic plasticity | |
| Strittmatter et al. | An intracellular guanine nucleotide release protein for G0. GAP-43 stimulates isolated alpha subunits by a novel mechanism. | |
| Wang et al. | Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation | |
| Risinger et al. | Differential phosphorylation of syntaxin and synaptosome‐associated protein of 25 kDa (SNAP‐25) isoforms | |
| Kubo et al. | Secreted Reelin molecules form homodimers | |
| Steiner et al. | Reticulon 1‐C/neuroendocrine‐specific protein‐C interacts with SNARE proteins | |
| Wolff et al. | Drug binding assays do not reveal specific binding of lacosamide to collapsin response mediator protein 2 (CRMP‐2) | |
| Yunoki et al. | Differential contribution of Kv4-containing channels to A-type, voltage-gated potassium currents in somatic and visceral dorsal root ganglion neurons | |
| Narayan et al. | Mu opioids induce biased signaling at the full-length seven transmembrane C-terminal splice variants of the mu opioid receptor gene, Oprm1 | |
| AU2002355997B2 (en) | Sodium channel regulators and modulators | |
| Daniels et al. | Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays | |
| Grant et al. | Opposing contributions of NR1 and NR2 to protein kinase C modulation of NMDA receptors | |
| Rutter et al. | Coexpression of postsynaptic density‐95 protein with NMDA receptors results in enhanced receptor expression together with a decreased sensitivity to L‐glutamate | |
| Reisinger et al. | The synaptophysin/synaptobrevin complex dissociates independently of neuroexocytosis | |
| AU2002355997A1 (en) | Sodium channel regulators and modulators | |
| EP1230551B1 (en) | Methods to identify compounds that modulate neuronal activity | |
| Gandini et al. | Regulation of CaV3. 2 channels by the receptor for activated C kinase 1 (Rack-1) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |